You are here

Gemcitabine/Paclitaxel Combination Approved as First-Line Treatment for Metastatic Breast Cancer

INDIANAPOLIS, IN -- May 19, 2004 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration has granted approval of Gemzar(R) (gemcitabine HCl), in combination with Taxol(R) (paclitaxel), providing a new option in first-line therapy for women battling metastatic breast cancer.

The FDA's approval marks the second indication in 2004 for a Lilly Oncology drug, and for Gemzar, specifically; this is the drug's third indication in the United States.

The approval of the Gemzar/Taxol combination was granted following analysis of Phase III data, which demonstrated superior treatment outcomes. Patients diagnosed with metastatic breast cancer and treated with a combination of Gemzar and Taxol experienced an improvement in time to disease progression and response rate compared to Taxol alone. The time to disease progression data (5.2 months vs. 2.9 months, respectively; p "In a disease that is marked by high recurrence rates, this added benefit is welcome news to patients and physicians," said Paolo Paoletti, M.D. vice president of oncology clinical research at Eli Lilly and Company (NYSE:LLY) . "The Gemzar/Taxol combination is one of the few combinations to surpass the single-agent efficacy of Taxol, and to do so with manageable side effects."

The official label on the approval states that Gemzar, in combination with paclitaxel, is approved in the United States for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.

In addition to the United States, Gemzar has been approved for this indication in 32 countries as of today.

Breast Cancer
According to the World Health Organization, more than 1 million cases of breast cancer will be diagnosed in 2004. Breast cancer is the most common malignancy in women. In the U.S., breast cancer is one of the leading causes of cancer deaths, with 40,580 estimated deaths in 2004. About 40 percent of breast cancer patients develop metastatic breast cancer after receiving treatment during the primary breast cancer phase and the average survival time for patients after diagnosis of metastatic disease is 18 to 30 months.

In the U.S., Gemzar was approved for the treatment of locally advanced or metastatic pancreas cancer in 1996 and, in combination with cisplatin, for the treatment of locally advanced or metastatic non-small cell lung cancer in 1998. Gemzar is approved in more than 90 countries and is the worldwide standard of care for pancreatic cancer and in many parts of the world for non- small cell lung, bladder and breast cancers. Gemzar is a nucleoside analogue that interferes with the process of DNA production; thereby preventing cancer cells from replicating and thus slows or stops tumor growth.

Source: Eli Lilly and Company

More Headlines

Synergistic Effects Seen When Combined With Cisplatin in Mice
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
For Locally Advanced or Metastatic Triple-Negative Type Only
41,000+ Medical Device Reports of Deaths, Serious Injuries, and Malfunctions in 7 Years
Purportedly Sterile Products Made in Unsanitary Conditions, Judge Says
Small-Molecule Drug Blocks Oxidative Stress Signals
MP-101 Has Potential to Drastically Alter Disease Progression